The main purpose of the Clinical Trial Modernization Act is to improve the way clinical trials are conducted and to make it easier for more diverse groups of people to participate in these trials. The goal is to ensure that clinical trials better reflect the populations that will ultimately use the medical products being tested, particularly those that are often underrepresented. Key provisions of the Act include several initiatives aimed at increasing participation from underrepresented populations.